6,678 trials
Pertussis · Tetanus · Diphtheria
Primary: Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix® — 273; 257; 5; 4…
Coronary Disease · Coronary Artery Disease · Coronary Restenosis
Primary: In-stent Late Loss (LL) — 0.39; 0.19 millimeters
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total…
Bipolar Disorder
Primary: Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2) — 1.00; 1.00; 0.98; 0.98 Proportion of…
Glaucoma, Open Angle · Ocular Hypertension
Primary: Stinging on Instillation — 0.6; 1.0; 0.6 Units on a scale
Diabetic Neuropathy, Painful
Primary: Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine — -2.12; -2.62 units on a scale — p=0.076
Healthy Subjects Without Type 1 Diabetes
Primary: Overall Mean Sensor Glucose by Age Group — 98; 103; 97; 96 mg/dL — p=0.009
Mucopolysaccharidosis VI · Maroteaux-Lamy Syndrome
Primary: Change in Height — 67.3; 80.3; 81.9; 91.3 centimeters
Alcoholism · Alcohol Abuse · Alcohol Dependence
Primary: Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week — -.30; -.20 Days/week — p=.012
Infection, Human Immunodeficiency Virus I · HIV Infection
Primary: Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48 — 0.22; 1.18…
Hepatitis B, Chronic · Cirrhosis · Fibrosis
Primary: Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population) — 52 participants
Healthy
Primary: Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an…
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1c Change From Baseline — -1.3; -1.9; -1.4 Percent
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score — 57.9; 58.2; 37.5; 28.3 OAB-q Score — p=<0.0001
Tobacco Dependence
Primary: Treatment-Related Adverse Events — 25.6; 39.1; 21.3; 0 Percentage of Participants